Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin  by Bar-Or, David et al.
Analytical Biochemistry 441 (2013) 13–17Contents lists available at SciVerse ScienceDirect
Analytical Biochemistry
journal homepage: www.elsevier .com/locate /yabioDipeptidyl peptidase IV activity in commercial solutions of human
serum albumin0003-2697  2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.ab.2013.06.002
⇑ Corresponding author at: Trauma Research Laboratory, Swedish Medical Center,
Englewood, CO 80113, USA. Fax: +1 303 788 4064.
E-mail address: dbaror@ampiopharma.com (D. Bar-Or).
1 Abbreviations used: cHSA, commercial human serum albumin; DA-DKP, aspartate-
alanine diketopiperazine; PBMC, peripheral blood mononuclear cell; DPP-IV, dipep-
tidyl peptidase IV; pNA, p-nitroaniline; rHSA, recombinant HSA; MWCO, molecular
weight cutoff; < 5-kDa, less than 5-kDa; LCMS, liquid chromatography mass
spectrometry; HPLC, high-performance liquid chromatography; ESI, negative elec-
trospray ionization; NAT, N-acetyl-tryptophan; ROS, reactive oxygen species.
Open access under CC BY license.David Bar-Or a,b,c,d,⇑, Denetta S. Slone e, Charles W. Mains d,f, Leonard T. Rael a,b
a Trauma Research Laboratory, Swedish Medical Center, Englewood, CO 80113, USA
bAmpio Pharmaceuticals, Greenwood Village, CO 80111, USA
cEmergency Department, Swedish Medical Center, Englewood, CO 80113, USA
dRocky Vista University, Parker, CO 80134, USA
e Trauma Services, Swedish Medical Center, Englewood, CO 80113, USA
f Trauma Services, St. Anthony Central Hospital, Lakewood, CO 80228, USAa r t i c l e i n f o
Article history:
Received 16 April 2013
Received in revised form 14 May 2013
Accepted 6 June 2013
Available online 14 June 2013
Keywords:
Human serum albumin
Dipeptidyl peptidase IV
Diketopiperazine
Cohn fractionation
Inﬂammationa b s t r a c t
Due to the heterogeneous nature of commercial human serum albumin (cHSA), other components, such
as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to the therapeutic effect of cHSA.
Here, we provide evidence for the ﬁrst time that DPP-IV activity contributes to the formation of aspar-
tate–alanine diketopiperazine (DA-DKP), a known immunomodulatory molecule from the N terminus
of human albumin. cHSA was assayed for DPP-IV activity using a speciﬁc DPP-IV substrate and inhibitor.
DPP-IV activity was assayed at 37 and 60 C because cHSA solutions are pasteurized at 60 C. DPP-IV
activity in cHSA was compared with other sources of albumin such as a recombinant albumin (rHSA).
In addition, the production of DA-DKP was measured by negative electrospray ionization/liquid chroma-
tography mass spectrometry (ESI/LCMS). Signiﬁcant levels of DPP-IV activity were present in cHSA. This
activity was abolished using a speciﬁc DPP-IV inhibitor. Fully 70 to 80% DPP-IV activity remained at 60 C
compared with the 37 C incubate. No DPP-IV activity was present in rHSA, suggesting that DPP-IV activ-
ity is present only in HSA produced using the Cohn fractionation process. The formation of DA-DKP at
60 C was observed with the DPP-IV inhibitor signiﬁcantly decreasing this formation. DPP-IV activity
in cHSA results in the production of DA-DKP, which could account for some of the clinical effects of cHSA.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.The use of commercial human serum albumin (cHSA)1 solutions
in the critically ill is sometimes indicated for blood volume restora-
tion in certain conditions such as burn, acute lung injury, and shock
[1–3]. For these patients, cHSA administration is controversial, with
recent evidence demonstrating at best no reduction in mortality
rates in comparison with cheaper alternatives such as saline [3]. In
addition, the heterogeneity of cHSA solutions has been demon-
strated and includes oxidation and truncation of the HSA molecule
[4]. During processing and storage of cHSA solutions, the protein
truncation occurs at the N terminus of the protein and results inthe cleavage of the ﬁrst two amino acids of HSA, Asp-Ala [5,6].
Due to the unique nature of the N terminus of HSA, this dipeptide
is further converted to a cyclic dipeptide termed aspartate–alanine
diketopiperazine (DA-DKP) [5]. In addition, the N terminus of HSA,
in conjunction with the nearby reduced cysteine-34 residue, is in-
volved in redox chemistry and the binding of redox-active metals
such as copper [7,8]. DA-DKP has been found in signiﬁcant quantities
in cHSA solutions, and DA-DKP itself has immunosuppressive effects
on activated peripheral blood mononuclear cells (PBMCs) and T-lym-
phocytes in vitro [9].
The mechanism of formation of DA-DKP from cHSA is currently
unknown, but auto-degradation of the N terminus and/or an enzy-
matic reaction involving a peptidase is possible. Dipeptidyl pepti-
dase IV (DPP-IV), or CD26, is a peptidase that preferentially
cleaves Xaa-Pro and Xaa-Ala dipeptides from the N terminus of
proteins [10]. DPP-IV activity has been reported on the cell surface
of immune and endothelial cells [11] as well as in blood serum as a
soluble form [12]. The main function of DPP-IV is thought to be the
modiﬁcation of biologically active peptides, cytokines, and other
cell surface proteins for the purpose of regulating the immune re-
sponse and cell differentiation [10]. In addition, a novel mechanism
Table 1
HPLC gradient used in separation of DA–DKP in < 5-kDa HSA solutions.
Time (min) A (%) B (%) C (%)
0 25 40 35
10 10 40 50
15 10 40 50
15.01 25 40 35
20 25 40 35
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the extracellular matrix (ECM), leading to the invasion of endothe-
lial cells into collagenous matrices [13].
Recently, an exhaustive proteomic analysis was performed on
cHSA solutions in order to understand the therapeutic effects, ad-
verse reactions, and mechanisms involved in treatments using
cHSA solutions [14]. In this study, a total of 1219 peptides corre-
sponding to 141 proteins different from HSA were identiﬁed. More
important, the peptidase DPP-IV was positively identiﬁed in the
cHSA solution. Therefore, due to its ability to cleave peptides after
an alanine residue, it is conceivable that DPP-IV is involved in the
formation of DA-DKP in cHSA solutions. To test this hypothesis,
commercially available solutions of HSA were assayed for DPP-IV
activity using a chromogenic substrate and a known DPP-IV inhib-
itor [10]. The presence of DPP-IV activity was also tested in a re-
combinant HSA source not produced via the Cohn fractionation
process. Finally, the effect of temperature on DPP-IV activity as
well as DA-DKP production in commercial solutions of HSA was
assessed.Materials and methods
Materials
Three commercially available, 250-ml, 5% (w/v) HSA products
(CSL Behring, Kankakee, IL, USA; Grifols Biologicals, Los Angeles,
CA, USA; and Octapharma USA, Hoboken, NJ, USA) were used
throughout the study. The N-terminal HSA peptide (DAHK) was
manufactured by Diosynth (The Netherlands). Recombinant HSA
(ecoHSA) was obtained from Genlantis (San Diego, CA, USA) and
was produced in the seeds of Asian rice (Oryza sativa). Synthetic
DA-DKP was produced by Syngene International (India). All other
reagents, including the DPP-IV substrate and inhibitor, were ob-
tained from Sigma–Aldrich (St. Louis, MO, USA).DPP-IV assay
DPP-IV activity was assayed by using a chromogenic substrate,
Gly-Pro-pNA (p-nitroaniline), as described previously [10]. All
reactions were carried out in DPP-IV assay buffer (pH 7.6) consist-
ing of 0.1 M Hepes, 0.12 M NaCl, 5 mM KCl, 8 mM glucose, and
10 mg/ml bovine serum albumin (BSA). cHSA (5%), recombinant
HSA (rHSA), and 0.9% NaCl (no-HSA control) were combined with
1 mM Gly-Pro-pNA (DPP-IV substrate) in assay buffer. Incubations
were performed at 37 or 60 C for 2 to 24 h. For DPP-IV inhibition
studies, 1 mM diprotin A in assay buffer was preincubated with the
HSA solutions for 15 min at 37 C prior to DPP-IV substrate addi-
tion. All incubations were read at 405 nm (SpectraMax M2 spectro-
photometer, Molecular Devices, Sunnyvale, CA, USA). Each reading
at 405 nm was corrected by subtracting the A405 for the DPP-IV
substrate-containing incubation from the corresponding A405 for
the negative control incubation for each HSA solution tested.Isolation of < 5-kDa HSA fraction
For the analysis of DA-DKP formation, an aliquot was added to a
microcentrifugal ﬁlter (Vivaspin 2, molecular weight cutoff
[MWCO] = 5000, Sartorius Stedim Biotech, Germany). Filters were
centrifuged at 3500 rpm for 30 min at room temperature. The less
than 5-kDa (< 5-kDa) fraction was collected and transferred to a
separate storage tube for liquid chromatography mass spectrome-
try (LCMS) analysis.LCMS assay
Each < 5-kDa fraction and DA-DKP synthetic standard (20–
2000 ng/ml) was spiked with 0.01 mM L-tryptophan-d5 (indole-
d5), which was used as an internal standard. An internal standard
was used to correct for any small changes in the consistency and
sensitivity of the LCMS between runs. Here, 50 ll was injected into
a strong anion exchange column (Spherisorb S5 SAX,
250  4.0 mM, Waters, Milford, MA, USA) connected to high-per-
formance liquid chromatography (HPLC) instrument (Waters
2795 Separations Module) coupled to a mass spectrometer (LCT-
TOF, Micromass, UK). A ternary mobile phase consisting of distilled
water (dH2O, solvent A), methanol (solvent B), and 200 mM ammo-
nium formate (pH 5.4, solvent C) was used at a ﬂow rate of 0.5 ml/
min using the gradient shown in Table 1.
The output of the HPLC instrument was split 1:20 (v/v) and in-
jected into the mass spectrometer using negative electrospray ion-
ization (ESI) with a scan range of m/z 80 to 1000, cone voltage of
30 eV, source temperature of 100 C, and gas temperature of
300 C. DA-DKP was measured by monitoring m/z 185, which cor-
responds to DA-DKP minus a single proton (–H+). The straight
chain of DA-DKP, Asp-Ala, can also be analyzed with this method
by monitoring m/z 203.Statistical methods
The amount of pNA produced (in lM) was calculated based on
the pNA molar extinction coefﬁcient in Hepes buffer [15]. Statisti-
cal analysis was performed using the software packages Excel
(Microsoft) and Matlab R13 (MathWorks). Groups were compared
using a two-tailed Student’s t test with a signiﬁcance level at
P < 0.05. All data are reported as means ± standard deviations.Results
DPP-IV activity was assessed in commercial preparations of
HSA. The activity assay chosen is well documented in the literature
and involves the cleavage of a known DPP-IV substrate, Gly-Pro-
pNA. The resulting liberation of a chromogen, pNA, was measured
spectrophotometrically at 405 nm. Three commercially available
solutions of 5% HSA were chosen with no particular manufacturer
preference. The only requirements were that the solutions were
unexpired and were produced by different manufacturers using
the Cohn fractionation process. For the incubation temperatures
of the enzyme assay, 37 and 60 C were chosen because the former
represents physiological conditions and the latter represents the
pasteurization temperature of cHSA solutions.
DPP-IV activity at 37 C was measured in all three 5% cHSA solu-
tions. All three cHSA solutions contained signiﬁcant DPP-IV activ-
ity, with the CSL Behring HSA having slightly less activity than
the Octapharma and Grifols HSAs (Fig. 1). The amount of DPP-IV
activity did not correlate with the expiration dates of the cHSA
sources. DPP-IV was completely suppressed in the presence of a
known DPP-IV inhibitor, diprotin A. This resulted in no additional
chromogen production during the entire incubation. In one of the
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Fig.1. DPP-IV activity in 5% cHSA solutions. DPP-IV activity (n = 3) is represented as
the total amount of pNA (in lM) produced during a 24-h incubation at 37 C with
(vertical lines) and without (solid bars) the DPP-IV inhibitor, diprotin A.
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Fig.3. DPP-IV activity in HSA solutions produced by different manufacturing
methods. DPP-IV activity (n = 3) is represented as the total amount of pNA (in
lM) produced during a 24-h incubation at 37 C. DPP-IV activity was measured in a
cHSA solution produced using Cohn fractionation (solid bars) and in an rHSA
solution (vertical lines). An asterisk (⁄) represents statistical signiﬁcance (P < 0.05).
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DPP-IV activity was present at signiﬁcant levels (Fig. 2). However,
DPP-IV activity at 60 C was approximately 70 to 80% of the origi-
nal DPP-IV activity at 37 C. At both temperatures, a dose response
in DPP-IV activity was observed with increasing concentrations of
the cHSA solution.
To compare DPP-IV activity in HSA isolated using a non-Cohn
fractionation process, an rHSA produced in rice was analyzed.
One of the cHSA solutions produced by Cohn fractionation was also
included in the DPP-IV activity assay. For both HSA types, concen-
trations ranged from neat solutions (5%, w/v) to diluted solutions
(1 and 2.5%). At all three concentrations, the amount of DPP-IV
activity in the cHSA solution was signiﬁcantly higher than that in
the rHSA solution (Fig. 3). In addition, DPP-IV activity in the rHSA
solutions was not statistically signiﬁcant from that in the assay
buffer-only incubations. Therefore, no signiﬁcant DPP-IV activity
was present in the rHSA solution.
The formation of the diketopiperazine, DA-DKP, was measured
in a cHSA solution heated at 60 C in the presence or absence of
a known DPP-IV inhibitor, diprotin A. The low-molecular-weight
fraction of HSA containing DA-DKP was isolated using a 5-kDa
MWCO spin column. The < 5-kDa fraction was assayed for
DA-DKP content by LCMS using ESI. During the ﬁrst 24 h,
DA-DKP content in the incubations containing no inhibitor in-
creased 30% from baseline DA-DKP levels (Fig. 4). In the presence0 5 10 15 20 25 30 
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5% HSA 
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Fig.2. Effect of temperature on DPP-IV activity in a solution of 5% cHSA. DPP-IV
activity (n = 3) is represented as the total amount of pNA (in lM) produced during a
2-h incubation at 37 C (solid bars) and 60 C (vertical lines).of the DPP-IV inhibitor, only a 10% increase in DA-DKP production
was observed over 24 h at 60 C.
Discussion
HSA is the most abundant circulating protein with ligand bind-
ing and transport properties, antioxidant functions, and enzymatic
activities [7]. Because HSA is important for the regulation of blood
volume and osmotic pressure in the critically ill, it is produced in
mass quantities by the pharmaceutical industry. The preferred
manufacturing technique of cHSA is based on the method of Cohn
and coworkers, which isolates HSA using a cold ethanol fraction-
ation process [16]. Commercial preparations of 5% HSA usually
contain the stabilizers N-acetyl-tryptophan (NAT) and sodium cap-
rylate at a concentration of 0.08 mmol/g HSA. The shelf life for
commercial solutions of HSA is commonly 3 years. Most likely
due to the production of reactive oxygen species (ROS), some
age-related changes in the solution properties have been observed,
including color changes, protein oxidation, proteolysis, aggrega-
tion, and precipitation [6].
Because the Cohn fractionation process is not speciﬁc for HSA,
some proteins and peptides are copuriﬁed with HSA and, therefore,
are present in commercial solutions [17]. In addition, because HSA
has the unique ability to bind multiple ligands, other peptides and
proteins with known biological activity have been identiﬁed in
commercial solutions of HSA using proteomic techniques [14,17].
These copuriﬁed or bound proteins include proteases (kallikrein,
cathepsin, carboxypeptidases, and dipeptidases), protease inhibi-
tors (kininogen), cell surface adhesion proteins (selectin, cadherins,
and ICAMs), and proteins involved in immunity (immunoglobulin
chains and components of the complement system) [14]. Recently,
a unique intrinsic proteolytic activity of the HSA molecule under
reducing conditions was documented [18]. Therefore, due to its
heterogeneous nature, the administration of HSA could introduce
potentially unwarranted side effects to critically ill patients.
In addition to proteins, commercial solutions of HSA contain a
small immunosuppressive molecule derived from the ﬁrst two
N-terminal amino acids of HSA, DA-DKP [9]. DA-DKP is thought
to modulate T-cell cytokine production by increasing Rap1
(Ras-related protein 1, a small GTPase) activity and decreasing acti-
vation factors relevant to the T-cell receptor signal transduction
pathway [19]. The mechanism of formation of DA-DKP in commer-
cial solutions of HSA is currently unknown, with one theory
suggesting the auto-degradation of the N terminus of HSA and
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Fig.4. DA-DKP production in 5% cHSA heated at 60 C. DA-DKP production (n = 3) was measured at different time points in a 5% cHSA solution heated at 60 C in the absence
(N) or presence (j) of a DPP-IV inhibitor. An asterisk (⁄) represents statistical signiﬁcance (P < 0.05) versus neat 5% HSA.
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teristics of the N terminus [5]. The theory explored in our study is
based on the existence of proteases in commercial solutions of
HSA, speciﬁcally DPP-IV [14]. Using a known chromogenic assay,
DPP-IV activity was indeed measured in three commercial solu-
tions of HSA. In addition, this activity was abolished by the use
of a known in vivo inhibitor of DPP-IV, diprotin A [20]. Therefore,
in addition to the presence of the DPP-IV protein, DPP-IV activity
is also present in commercial solutions of HSA. This activity was
not present in an rHSA, suggesting that DPP-IV activity in cHSA is
not removed during the Cohn fractionation process. Other prote-
ases that have enzymatic activity on DPP-IV substrates, such as
DPP-8 and DPP-9, were not included in this study because they
have not been positively identiﬁed in cHSA. This is probably due
to the fact that they are not secreted proteins (UniProt search)
and, therefore, are unlikely to be present in a plasma-derived
solution such as cHSA.
During the production of cHSA, the product is pasteurized for 10
to 11 h by heating at 60 C. Interestingly, optimal DPP-IV activity
has been reported between 50 and 60 C in serum, recombinant,
and seminal DPP-IV, with a gradual loss in activity at 65 C [12].
This unique characteristic of DPP-IV makes it a plausible candidate
for the production of DA-DKP in cHSA solutions. In addition, during
the Cohn fractionation process, the low-molecular-weight compo-
nents (other than those bound to HSA) are most likely removed
prior to the pasteurization step. Therefore, the majority of
DA-DKP measured in commercial solutions of HSA is produced
de novo from the pasteurization step onward. In the cHSA solu-
tions used for this study, signiﬁcant DPP-IV activity was measured
at 60 C. However, the total activity was only 70 to 80% of the
activity present in the 37 C incubations. The amount of DA-DKP
produced at 60 C in this study has been shown to cause signiﬁcant
immunosuppression in activated human PBMCs [9].
The production of DA-DKP in cHSA at 60 C was examined using
an LCMS method for detecting DA-DKP. In the neat solutions of
cHSA, DA-DKP was produced in signiﬁcant quantities over 24 h at
60 C. When the DPP-IV inhibitor, diprotin A, was added to the
cHSA solutions, the amount of DA-DKP produced at 60 C de-
creased approximately 3-fold over the 24-h period. Therefore, this
ﬁnding suggests that DPP-IV is partially responsible for the forma-
tion of DA-DKP in commercial solutions of HSA. Diprotin A did not
completely abolish DA-DKP formation at 60 C. Diprotin A istrapped as a tetrahedral intermediate covalently bound to Ser630
inside the active site of DPP-IV [21]. Interestingly, diprotin A (Ile-
Pro-Ile) is a substrate of DPP-IV, with a low turnover leading to
an apparent competitive inhibition [22]. It is possible that diprotin
A is hydrolyzed to a sufﬁcient degree after a 24-h incubation at
60 C to allow other DPP-IV substrates into the active site such as
the N terminus of HSA. In combination with the enzymatic forma-
tion of DA-DKP, we cannot completely discount the formation of
DA-DKP via the auto-degradation of the N terminus of HSA [5].
The known substrates of DPP-IV include several chemokines,
cytokines, neuropeptides, circulating hormones, and bioactive pep-
tides [23]. One of the most studied DPP-IV substrates is glucagon-
like peptide 1 (GLP-1), which regulates circulating plasma glucose
levels and, therefore, is important in the etiology of type 2 diabetes
[21]. All of the known DPP-IV substrates are polypeptides, with the
N terminus of HSA never being described as a substrate until now.
Access of the N terminus of HSA to the DPP-IV active site is unlikely
to occur with HSA in its native conﬁrmation due to steric hin-
drance. However, a signiﬁcant portion of the HSA N terminus needs
to be accessible to the DPP-IV active site in order to form DA-DKP.
In our study, we used the HSA N-terminal peptide DAHK as a DPP-
IV substrate, but we detected only the formation of the straight
chain dipeptide (i.e., Asp-Ala) instead of DA-DKP (data not shown).
There are at least two plausible ways in which the N terminus of
HSA can be presented to the active site of DPP-IV. First, the oxida-
tion of HSA in commercial solutions during storage could cause the
cleavage of HSA, resulting in the production of N-terminal peptides
that are better substrates for the DPP-IV-active site. Redox-active
metals, such as iron and copper, are found in signiﬁcant quantities
in solutions of cHSA [24]. Indeed, the N terminus of HSA binds cop-
per, which could result in the in situ production of ROS, possibly
leading to the cleavage of HSA N-terminal peptides [8]. Second,
slow denaturation of HSA could result in the unfolding of the N ter-
minus, making it a more accessible DPP-IV substrate. This is par-
tially supported by the fact that at 60 C HSA is in a reversible
unfolded form, possibly exposing the N terminus [25]. Is it possible
that this reversible unfolded form becomes more common during
the prolonged storage of solutions of HSA, leading to the increased
production of DA-DKP?
The immunosuppressive capabilities of administered HSA are
well documented. In a rat model of hemorrhagic shock, HSA re-
duced lung permeability and neutrophil sequestration in a dose-
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tered HSA signiﬁcantly down-regulated the expression of integrins
and ICAM-1, factors involved in the adhesion of immune cells to
the endothelium [27]. HSA also suppressed the respiratory burst
of neutrophils in response to TNFa or complement exposure,
resulting in the selective and reversible inhibition of neutrophil
spreading [28]. Finally, HSA was found to be the least pro-inﬂam-
matory of the resuscitation ﬂuids used in a hemorrhagic shock
model [29]. Based on our previous immunological studies, DA-
DKP appears to be partially responsible for the immunosuppressive
capabilities of HSA.
The heterogeneity of commercial solutions of HSA could cause
many beneﬁcial or detrimental effects in critically ill patients,
depending on the immunological state of the patients. Some of
the compounds recently identiﬁed in commercial solutions of
HSA are involved in immune regulation and function [14]. In addi-
tion, the stabilizer NAT is a well-known antagonist of the neurok-
inin-1 receptor, an important mediator of the immune and
inﬂammatory response as well as vascular permeability [30]. In
our study, we focused on the mechanism of formation of the
anti-inﬂammatory DA-DKP, which is found in micromolar concen-
trations in commercial solutions of HSA. Commercial solutions of
HSA contain signiﬁcant levels of DPP-IV activity, which is inhibited
by diprotin A. In addition, DPP-IV activity is unique to the cHSA
solutions due to the Cohn manufacturing process, which isolates
other plasma components such as DPP-IV. Finally, the de novo for-
mation of DA-DKP in cHSA solutions heated at 37 C was observed
with a corresponding inhibition of formation in the presence of
diprotin A. Therefore, in commercial solutions of HSA, the pepti-
dase DPP-IV appears to be involved in the formation of DA-DKP,
a known anti-inﬂammatory compound.
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